In-utero treatment reverses cleft palate in mice

September 13, 2017, University of Utah Health
In a Pax9+/+ embryo at E18.5, normal palatal fusion with parallel rugae arrangement is visible. Credit: Rena D'Souza

Researchers at University of Utah Health clarified a molecular pathway responsible for the formation of cleft palate and identified a new treatment to reverse this defect in mouse pups in-utero. These findings, published on September 5 in the journal Development, offer a new way to think about cleft development and could potentially yield treatments to prevent this common birth defect in people.

"As a clinician, I understand the devastating consequences of ," said Rena D'Souza, D.D.S., Ph.D., professor of Dentistry at U of U Health.

Cleft palate is one of the most common birth defects, affecting 6 in 2,651 children born in the United States. The forms when the bony tissue covering the roof of the mouth fails to join during pregnancy. Children with a cleft palate require reconstructive surgery and complex life-long treatments.

D'Souza and her team originally set out to investigate a different tissue: teeth. Using mice as a model, they had planned to clarify the role of two sets of - PAX 9 and Wnt genes - in regulating tooth formation. Unexpectedly, their work revealed how the interplay between these two genes at a critical window of development is needed for the palatal shelves to grow and fuse in the midline.

"It was really serendipitous," she said. "For the first time, we can show the involvement of the Wnt pathway during palate fusion."

Like people born with a cleft palate, the two sides of the palate fail to fuse in mice lacking the gene PAX9. At the molecular level, D'Souza found another abnormality. The mice missing this gene had an increase in two genes, called Dkk1 and Dkk2, that block the Wnt signaling pathway.

D'Souza research team. Credit: University of Utah Health

D'Souza attempted to rectify that change by administering a pharmacological Wnt-based treatment that inhibited Dkk (WAY-262611) intravenously through the mother rat's tail vein during a critical window of the pups' gestation, when palate formation is initiated and ongoing.

Treatment restored palate fusion in all of the pups tested. The drug works by blocking the Dkk genes and restoring the Wnt pathway.

The researchers found no adverse health effects after monitoring the mother mice and their pups exposed to the treatment for 18-months.

Along with cleft defects, PAX9-deficient pups also experience defects in their hind limb, as well as parathyroid and thymus glands. The Wnt-based treatment did not prevent the other defects, and the PAX9-deficient pups soon died after birth. D'Souza believes the premature death is more likely related to abnormal calcium levels, contrary to previous claims that early death was due to malformed palate.

D'Souza acknowledges that more work is necessary to ensure the Wnt-based therapy does not affect other organ systems negatively or produce long-term health problems.

Cleft palate in a Pax9-/- embryo. Credit: Rena D'Souza

"These seminal findings are exciting for the field, because Dr. D'Souza and her team have opened an interesting door into potential pharmacological therapies," said Ophir Klein, M.D., Ph.D., Chief of Genetics at the University of California San Francisco. Klein, who is not an author on the study, believes it presents a new strategy for the of single-gene disorders in humans, which can be exploited for new approaches to reverse these defects in humans.

D'Souza believes these findings offer some babies born with cleft palate something that was missing before, hope.

"Clearly, there is more work to be done prior to implementation for humans, but it seems feasible to translate this research into Wnt-based treatments for people," she said. Future work is necessary to investigate if it is safe and effective to deliver a drug to human babies in-utero or directly to newborns with palate defects.

Explore further: Small molecule replacement therapy to rescue craniofacial defects

More information: Shihai Jia et al, Small-molecule Wnt agonists correct cleft palates in Pax9 mutant mice in utero, Development (2017). DOI: 10.1242/dev.157750

Related Stories

Small molecule replacement therapy to rescue craniofacial defects

March 19, 2016
Today at the 45th Annual Meeting & Exhibition of the American Association for Dental Research, researcher Shihai Jia, University of Utah, Salt Lake City, USA, will present a study titled "Small Molecule Replacement Therapy ...

Epilepsy drug may not increase risk of birth defects

April 6, 2016
Babies born to pregnant women taking the epilepsy drug lamotrigine may not be at an increased risk of birth defects, such as cleft lip, cleft palate or clubfoot, according to a study published in the April 6, 2016, online ...

Cleft palate discovery in dogs to aid in understanding human birth defect

April 7, 2014
UC Davis School of Veterinary Medicine researchers have identified the genetic mutation responsible for a form of cleft palate in the dog breed Nova Scotia Duck Tolling Retrievers.

Understanding genetic synergy in cleft palate

July 19, 2017
Like all of the individual elements of fetal development, palate growth is a marvel of nature. In part of this process, ledges of tissue on the sides of the face grow downwards on each side of the tongue, then upward, fusing ...

Epigenetics could help diagnose different types of cleft

June 15, 2017
Cleft lip and/or palate are common birth defects and affect around 15 in every 10,000 births in Europe. New research by the University of Bristol from the largest study of cleft lip and/or palate in the world, the Cleft Collective, ...

Recommended for you

Add broken DNA repair to the list of inherited colorectal cancer risk factors

February 23, 2018
An analysis of nearly 3,800 colorectal cancer patients—the largest germline risk study for this cancer to date—reveals opportunities for improved risk screening and, possibly, treatment.

Team identifies genetic defect that may cause rare movement disorder

February 22, 2018
A Massachusetts General Hospital (MGH)-led research team has found that a defect in transcription of the TAF1 gene may be the cause of X-linked dystonia parkinsonism (XDP), a rare and severe neurodegenerative disease. The ...

Defects on regulators of disease-causing proteins can cause neurological disease

February 22, 2018
When the protein Ataxin1 accumulates in neurons it causes a neurological condition called spinocerebellar ataxia type 1 (SCA1), a disease characterized by progressive problems with balance. Ataxin1 accumulates because of ...

15 new genes identified that shape human faces

February 20, 2018
Researchers from KU Leuven (Belgium) and the universities of Pittsburgh, Stanford, and Penn State have identified 15 genes that determine facial features. The findings were published in Nature Genetics.

New algorithm can pinpoint mutations favored by natural selection in large sections of the human genome

February 20, 2018
A team of scientists has developed an algorithm that can accurately pinpoint, in large regions of the human genome, mutations favored by natural selection. The finding provides deeper insight into how evolution works, and ...

New software helps detect adaptive genetic mutations

February 20, 2018
Researchers from Brown University have developed a new method for sifting through genomic data in search of genetic variants that have helped populations adapt to their environments. The technique, dubbed SWIF(r), could be ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.